EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Activated phosphoinositide 3‐kinase delta syndrome: Pathogenesis, clinical manifestations, and treatment

Ke Zhu, Qifan Li, Lingli Han, Jinqiao Sun iD

Pediatric Discovery · 2024-09 · 2 (3)

DOI: 10.1002/pdi3.2504 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pediatric Discovery, online erschienen am 23.08.2024. Verfasst von Ke Zhu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology National Children Medical Center Children's Hospital of Fudan University Shanghai China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Activated phosphoinositide 3‐kinase delta syndrome (APDS) is an autosomal dominant inborn errors of immunity resulting from gain of function mutations in the PIK3CD gene or loss of function mutations in the PIK3R1 gene. These mutations lead to hyperactivation of the phosphoinositide 3‐kinase/Akt/mammalian target of rapamycin (mTOR) signaling pathways, causing complex deficiencies in cellular and humoral immunity. APDS patients exhibit diverse clinical manifestations including recurrent respiratory infections, nonneoplastic lymphoproliferation, an increasing risk of malignancy, and autoimmune diseases. Neurodevelopmental abnormalities, short stature, failure to thrive, and psychological disorders are also observed. Management strategies for APDS involve antibiotic prophylaxis and immunoglobulin replacement therapy, immunosuppressive therapies, and hematopoietic stem cell transplantation for severe cases. Targeted therapies, such as the mTOR inhibitor sirolimus and the elective Phosphoinositide 3‐kinase delta inhibitor leniolisib, have emerged as promising options, demonstrating both safety and effectiveness. Continuous monitoring and further research are essential to optimize treatment strategies and understand the long‐term implications of these interventions. This review aims to summarize the pathogenesis, clinical manifestations, and treatment of APDS.

Schlagwörter

Stichwörter der Autor:innen

activated phosphoinositide 3‐kinase delta syndromehematopoietic stem cell transplantationinborn errors of immunitytargeted therapy

Autor:innen und Institutionen

  • Department of Clinical Immunology National Children Medical Center Children's Hospital of Fudan University Shanghai China.

ORCID-Profile: Jinqiao Sun

Zitieren

APA

Zhu, K., Li, Q., Han, L., & Sun, J. (2024). Activated phosphoinositide 3‐kinase delta syndrome: Pathogenesis, clinical manifestations, and treatment. Pediatric Discovery, 2(3). https://doi.org/10.1002/pdi3.2504

Vancouver

Zhu K, Li Q, Han L, Sun J. Activated phosphoinositide 3‐kinase delta syndrome: Pathogenesis, clinical manifestations, and treatment. Pediatric Discovery. 2024;2(3). doi:10.1002/pdi3.2504

BibTeX
@article{Zhu2024,
  author = {Zhu, Ke and Li, Qifan and Han, Lingli and Sun, Jinqiao},
  title = {Activated phosphoinositide 3‐kinase delta syndrome: Pathogenesis, clinical manifestations, and treatment},
  journal = {Pediatric Discovery},
  year = {2024},
  volume = {2},
  number = {3},
  doi = {10.1002/pdi3.2504}
}
Kostenlos starten →